OMCL Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $314 million for Q4 2025, up 2% year-over-year and 1% quarter-over-quarter.

Product Revenue: $180 million, down 1% year-over-year but up 1% sequentially.

Service Revenue: $134 million, an 8% increase year-over-year and 1% quarter-over-quarter.

Annual Recurring Revenue (ARR): Exited 2025 at $636 million, a 10% increase from 2024.

GAAP EPS: Loss of $0.05, compared to a profit of $0.34 in Q4 2024.

Non-GAAP EPS: $0.40, down from $0.60 in Q4 2024.

Gross Margin: Non-GAAP gross margin at 43.2%, down from 47.4% in 2024.

Free Cash Flow: $18 million in Q4 2025, down from $43 million in Q4 2024.

Cash and Cash Equivalents: $197 million as of December 31, 2025, down from $369 million in 2024.

2Strategic Updates and Business Highlights

Product Launches: Introduced Titan XT, a new automated dispensing system, at the ASHP annual meeting, receiving positive initial feedback.

Market Expansion: Focused on expanding product footprint in inpatient and outpatient care settings, with notable wins in major health systems and government facilities.

Technology Platform: Continued development of Omnisphere, a cloud-native platform for medication management, achieving high-trust certification.

Competitive Positioning: Strong demand for point-of-care solutions, with significant wins across the U.S. and Canada, including contracts with the Department of Veteran Affairs.

3Forward Guidance and Outlook

Q1 2026 Guidance: Total revenue expected between $300 million and $310 million; product revenue between $171 million and $176 million.

Full Year 2026 Guidance: Total revenue anticipated between $1.215 billion and $1.255 billion; product bookings between $510 million and $560 million; ARR expected to reach $680 million to $700 million.

Long-Term Growth Strategy: Focus on scaling recurring revenue and expanding market presence, with expectations of a $2.5 billion refresh cycle opportunity for Titan XT.

4Bad News, Challenges, or Points of Concern

Declining Gross Margins: Non-GAAP gross margin decreased due to tariff costs and unfavorable product mix, with projected tariff impacts of $15 million in 2026.

GAAP EPS Loss: Transitioning to a loss in Q4 2025 raises concerns about profitability.

Competitive Pressures: The competitive landscape remains challenging, with significant market share opportunities but also risks associated with customer retention and conversion from competitors.

Economic Uncertainty: Potential regulatory and tariff uncertainties could impact future performance.

5Notable Q&A Insights

Product Cycle Expectations: Management indicated that the Titan XT refresh cycle could mirror the previous product cycles, with a significant opportunity for competitive conversions.

Sales and Marketing Investments: Plans to increase investments in sales and clinical education to capitalize on market opportunities.

Customer Feedback on XT Xtend: Customers who invested in XT Xtend are still able to access cloud capabilities, indicating a flexible upgrade path.

ERP System Implementation: Acknowledged $10 million in expenses for ERP updates in 2026, with expectations for long-term efficiency gains. Overall, Omnicell reported a solid finish to 2025 with strategic advancements and positive customer feedback on new products, despite facing margin pressures and a competitive landscape. The company remains optimistic about its growth trajectory into 2026 and beyond.